The US Food and Drug Administration has given the green light to a new monoclonal antibody called donanemab, developed by Eli Lilly, to help slow the progression of early symptomatic Alzheimer's disease. Priced at $695 per vial, the treatment, known as Kisunla, is aimed at reducing amyloid plaque buildup in the brain, a key characteristic of Alzheimer's.
While not a cure, clinical trials have shown that donanemab can significantly slow the advancement of the disease, enabling patients to maintain independence and engage in daily activities for longer periods.
